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Abstract Developing procedures for the derivation of
human pluripotent stem cells (PSCs) gave rise to novel
pathways into regenerative medicine research. For many
years, stem cells have attracted attention as a potentially
unlimited cell source for cellular therapy in neurodegen-
erative disorders, cardiovascular diseases, and spinal cord
injuries, for example. In these studies, adult stem cells were
insufficient; therefore, many attempts were made to obtain
PSCs by other means. This review discusses key issues
concerning the techniques of pluripotent cell acquisition.
Technical and ethical issues hindered the medical use of
somatic cell nuclear transfer and embryonic stem cells.
Therefore, induced PSCs (iPSCs) emerged as a powerful
technique with great potential for clinical applications,
patient-specific disease modelling and pharmaceutical
studies. The replacement of viral vectors or the adminis-
tration of analogous proteins or chemical compounds
during cell reprogramming are modifications designed to
reduce tumorigenesis risk and to augment the procedure
efficiency. Intensified analysis of new PSC lines revealed
other barriers to overcome, such as epigenetic memory,
disparity between human and mouse pluripotency, and
variable response to differentiation of some iPSC lines.
Thus, multidimensional verification must be conducted to
fulfil strict clinical-grade requirements. Nevertheless, the
first clinical trials in patients with spinal cord injury and
macular dystrophy were recently carried out with differ-
entiated iPSCs, encouraging alternative strategies for
potential autologous cellular therapies.
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Introduction
The primary potential of stem cells lies is their self-re-
newal abilities and their possibility of giving rise to
approximately 220 different types of specialized cells. In
stem cell hierarchy, totipotent cells have an unlimited
differentiation spectrum—they are able to form both the
embryo and the placenta. In turn, pluripotent cells dif-
ferentiate into all three embryonic germ layers: the
endoderm, leading to the development of gastrointestinal
tract, stomach and lungs; the mesoderm, within which are
formed muscles, bones, the urogenital tract, and blood;
and the ectoderm, responsible for the development of
nervous system and epidermal tissue generation. Thus, in
contrast to multipotent cells, which form only limited
number of cell lineages within the three embryonic layers,
pluripotent cells are able to differentiate into any mature
cell type. This feature allows a real opportunity to renew
non-functional damaged tissues caused by common dis-
eases, such as spinal cord injury, Parkinson’s and
Huntington’s diseases, type 1 diabetes, cardiovascular and
haematological diseases, osteoarthritis, kidney failure, and
stroke (Badger et al. 2014; Bauwens et al. 2011; Blin
et al. 2010; Iglesias-Garcı´a et al. 2013; Kawamura et al.
2012; Kaye and Finkbeiner 2013; Meissner and Jaenisch
2006; Okano et al. 2013; Singla et al. 2011; Thatava et al.
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Stem cells occur also in non-embryonic tissues of adult
organisms. Precursors of stem cells may spontaneously
repair damaged tissues and organs such as bone marrow,
gut, and liver. They reside in a special microenvironment
called the stem cell niche. Some of these can differentiate
into other cell type lineages (Jopling et al. 2011; Li et al.
2005).
Currently, some non-embryonic stem cell (non-ESC)
transplantations have been implemented in medical prac-
tice, especially in haematology associated with malignancy
therapy. Human hematopoietic cells derived from bone
marrow, peripheral blood or umbilical cords help to treat
individuals undergoing cancer treatment. Chemotherapy-
induced bone marrow ablation can be replaced with other
bone marrow transplanted stem cells (Copelan 2006).
Unfortunately, adult stem cells (ASCs) are relatively
rare and in the bone marrow, hematopoietic stem cells are
estimated to be less than 1 in 10,000 cells (Domen et al.
2006). Additionally, non-ESCs have some limitations for
application in cellular therapies. A low capacity to self-
renew in laboratory conditions reduces the possibility of
their efficient multiplication.
Such obstacles prompted scientists to reprogram somatic
cells into pluripotent cells in individual patients. Until
recently, somatic cell nuclear transfer (SCNT) was the
primary technique for producing genetically matched cells
and tissues that may potentially cure the diseases of civi-
lization (Gurdon 1962a). The procedure is based on
transferring a nucleus from a somatic cell into the enu-
cleated egg. Despite the great progress made in SCNT
research in the mouse model, many difficulties appearing in
primate cloning have to be overcome to introduce thera-
peutic applications in humans (Byrne et al. 2007).
Another approach bypassing the use of embryonic cells
was a transfection procedure forcing the expression of
Oct4, Sox2, Klf4 and c-Myc genes, reported by Takahashi
and Yamanaka (2006). They induced pluripotent stem cells
(iPSCs) from mouse fibroblasts. One year later the exper-
iment succeeded with human cells (Takahashi et al. 2007).
This technique opened a new field of stem cell research for
the generation of PSC lines that can be genetically cus-
tomized for the patient, thus lowering the immune rejection
risk. Currently, studies have aimed to implement the
technique while excluding carcinogenesis and boosting the
reprogramming efficiency by improving transduction sys-
tems to augment pluripotency potential.
These and other studies have led to a better under-
standing of the mechanism of pluripotency maintenance. In
addition to the pluripotency genes, three principal cytoki-
nes are significantly involved in this process: fibroblast
growth factor (FGF)-2, transforming growth factor (TGF)-
b/bone morphogenic protein (BMP; especially activin-A)
and Wingless-related integration site family of proteins
(WNTs) (Sato et al. 2003). Otherwise, critical homologous
gene sets responsible for stemness are induced in pluripo-
tent cells, such as the POU domain, class 5 transcription
factor 1 (OCT4), the NANOG homeobox, and the sex
determining region Y-box 2 (SOX2) (Abeyta et al. 2004).
These gene sets work within an autoregulatory loop which
activates other pluripotency-linked genes (their number is
estimated as approximately 350 genes) and repress differ-
entiation-related genes (Boyer et al. 2005). A negative
feedback with Foxd3 ensures stable Oct4 expression and
maintenance of pluripotency (Pan et al. 2006).
Direct PSC Sampling
PSCs can be obtained from a fertilized embryo growing
in vitro for 5 days, the human early stage blastocyst
(Thomson et al. 1998). At this stage, the structure consists
of the trophoblast, forming the placenta, and the blasto-
coele, a fluid filling the cavity, and the inner cell mass
(ICM), which gives a rise to a foetus. If there were not
ethical concerns, this could provide a theoretically unlim-
ited supply of PSCs. Currently, there are six primary
approaches to establish human PSC lines from embryonic
or foetal tissues, as follows.
– Traditional human ESC (hESC) line generation (em-
bryonic derivative): the first hESC line was generated
by Thomson et al. (1998) using ICM from spare in vitro
fertilized embryos at the blastocyst phase. ICM cells
are pluripotent, with the ability to become any type of
cell other than the umbilical cord and the placenta.
Following dissection or immunosurgery, ICMs are
plated onto an irradiated mouse fibroblast feeder layer
and cultured in high serum-containing growth factors
medium (Thomson et al. 1998).
– Human primordial germ cells: Gearhart and co-workers
isolated primordial germ cells from a 5- to 7-week-old
embryo and established embryonic germ cell lines
(Shamblott et al. 1998). The issue with this technique
was spontaneous undirected cell differentiation.
– ESCs from dead embryos: this technique uses embryos
that stopped dividing after in vitro fertilization (Zhang
et al. 2006).
– hESC derivatives from genetically abnormal embryos:
embryos with diagnosed genetic disorders were
employed to obtain hESC lines to understand the
mechanism of disorders such as Huntington’s disease,
Marfan syndrome, muscular dystrophy and thalassemia
(Verlinsky et al. 2005).
– Single cell embryo biopsy as hESC line source: this
technique exploits single cells from pre-implanted
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human embryos without affecting blastocyst viability
(Chung et al. 2006).
– hESC generation via parthenogenesis: in this study, a
human embryo was generated without fertilization by
sperm. The egg was physically triggered to mimic a
fertilization event and subsequently divided and formed
a blastocyst (Revazova et al. 2007). In this case,
pluripotent human stem cells bear genetic information
only of egg origin.
All of these methods involve the isolation of pluripotent
cells at an early developmental phase followed by culturing
cells in vitro. Growing hESCs in culture and maintaining
them in a self-renewal and pluripotent state with a
stable karyotype is difficult and requires highly specialized
techniques. It is frequently supported by mouse or human
feeder layers (Richards et al. 2002) or conditioned media in
feeder-free culture systems (Xu et al. 2001). Inactivated
(stopped cell divisions) feeder layer cells secrete necessary
nutrients and proteins promoting growth and detoxifying
the culture medium, inter alia, FGF-2 and BMP inhibitor
(Dahl et al. 2003; Xu et al. 2005). Fibroblast feeder cells
also express adhesion molecules and extracellular matrices,
promoting the attachment of pluripotent cells. However,
there can be contamination during the later differentiation
process (e.g., cross-transferring xenogeneic factors). Thus,
these cells must be subsequently removed or replaced with
matrix proteins; e.g., Matrigel, laminin (Xu et al. 2001) or
synthetic polymers (Mei et al. 2010). This is also the reason
for exchanging culture media with defined media; e.g.,
knockout serum replacement medium, mTeSR1 medium
and xeno-free media such as NutriStem (Sugii et al. 2010),
TeSR2 (Meng et al. 2012), Essential 8 (Chen et al. 2011)
and StemFit (Nakagawa et al. 2014). These are important
media for future clinical therapy because animal-derived
products may introduce exogenous antigens, pathogens and
viruses to the cell population.
The techniques described above involve the destruction
of embryos during in vitro fertilization procedures, which
prevents wider deployment. However, it is possible to
derive new hESC lines using only a single blastomere by
culturing the embryo with a mixture of human laminin LN-
521, an adhesion protein occurring in ICM, and E-CAD-
HERIN, providing intercellular contact triggering signals
(Hovatta et al. 2014). Family specific lines provide
advantages requiring a lower dose of immunosuppressants
and excluding the extensive formation of banks of haplo-
types that represent most human leukocyte antigen
histocompatibility classes and ensure the generation of
many cell types for cell therapy purposes (Jacquet et al.
2013).
Nevertheless, many ethical concerns related to embry-
onic cells prompted scientists to investigate new directions
in stem cell generation. In 2003, there was some interest in
the OCT-4 positive cells from the amniotic fluid that sur-
rounds the foetus (Prusa et al. 2003). It was possible to
differentiate them into three embryonic germ layers, and
after transferring them into an immunocompromised ani-
mal model, no tumor formation was observed. Initial
differentiation attempts resulted in the generation of human
neuronal, liver and bone cells (Hauser et al. 2010). This
research initiated the non-ESC line known as amniotic
fluid-derived stem cells (AFS). However, AFSs did not
produce all proteins typical for PSCs.
Somatic Cell Nuclear Transfer
Ethical controversies and a shortage of ASCs forced sci-
entists to search for alternative sources of PSCs. One of the
options was ‘‘reprogramming’’ somatic cells, which can be
accomplished with SCNT to an enucleated egg.
The idea of nuclear transfer first appeared at the end of
19th century. The first experiments were conducted on fish
and amphibian eggs because of their large size and
unlimited resources (Spemann 1938). As early as 1962,
John Gurdon’s studies on the vertebrate somatic cell
nucleus suggested the possibility of ‘‘reprogramming’’
somatic cells into an embryonic state. He transferred a
nucleus from a differentiated intestinal epithelial cell into
an enucleated egg of Xenopus laevis. This technique suc-
cessfully formed a fertile adult frog (Gurdon 1962b). A few
decades later, this method was successfully used for
mammalian somatic cell nucleus transfer by Ian Wilmut
and Keith Campbell (Wilmut et al. 1997). To date, there
have been approximately 15 mammalian species cloned,
including the mouse (Wakayama et al. 1998), pig (Pole-
jaeva et al. 2000), rabbit (Chesne´ et al. 2002), dog (Lee
et al. 2005), buffalo (Shi et al. 2007) and camel (Wani et al.
2010). Issues that emerged during the procedure were
connected with developmental arrest soon after implanta-
tion, abnormal gene expression, incomplete genetic
reprogramming and a low success rate, below 5 %
regardless of the species used (Wakayama 2007). In addi-
tion, cloned animals were affected with frequent
pathologies of the brain and kidney, diabetes, obesity, and
large offspring syndrome, for example.
To obtain human stem cells via SCNT, human oocytes
can be derived from a donor after stimulation with gona-
dotropins to produce a range of oocytes during the
hyperovulation process. The nucleus from the oocyte is
then removed and replaced with a nucleus from a somatic
differentiated cell of another person. Next, the egg is
stimulated by electrical impulses to divide to the blastocyst
stage. Then, cells of the inner cell mass are extracted and
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used to start cultures of ESCs. The procedure can also be
performed with nuclei at the blastocyst stage, as reported
for two primate species, macaques (Byrne et al. 2007) and
humans (French et al. 2008). Somatic cell nuclear transfer
was performed with fibroblast nuclei and cultured up to the
blastocyst stage. To date, much progress in ESC research
has been achieved in the mouse model, whereas in humans,
unexpected difficulties appeared concerning reprogram-
ming and the epigenetic status of somatic cell nuclei (Yu
et al. 2009b). The first attempts using this technique in
humans were carried out by American Cell Technologies in
1998 using a human skin cell and an enucleated egg from a
cow. The hybrid human clone developed an embryo that
was destroyed after 12 days. Lately, a wide range of cell
types, derivatives of all the three embryonic germ layers,
have been differentiated from ESCs (obtained by SCNT);
e.g., neural cells (Barberi et al. 2003) and/or cardiomy-
ocytes (Lu¨ et al. 2008).
The factors responsible for nuclear reprogramming are
found primarily in the oocyte cytoplasm. DNA methylation
and histone modification play a paramount role influencing
genomic imprinting, X chromosome inactivation, cell dif-
ferentiation, chromosome structure, cell senescence and
apoptosis (Bird 2002). DNA methylation in SCNT embryos
is at much higher level than in normal embryos. This may
be the reason why demethylation and de novo methylation
in the somatic cell donor nucleus is not as efficient,
resulting often in incomplete reprogramming. Moreover,
the somatic nucleus is subjected to histone reacetylation.
The epigenetic marks of histones must be erased and
reestablished before embryonic transfer to the recipient
mother. Due to hyperacetylation in the somatic nucleus,
aberrant histone modifications may occur in cloned
embryos (Wang et al. 2007). Hence, to obtain the totipotent
state, inhibitors of histone deacetylase (HDAC) have been
used, such as trichostatin A. Simultaneously, they
improved nuclear remodelling by establishing and main-
taining a zygotic-like chromatin structure (Maalouf et al.
2009).
A variation of the classical SCNT has been to turn off
the Cdx2 gene (required for implantation in the uterus).
The procedure of patient-specific stem cell development is
called altered nuclear transfer and does not entail the
destruction of the embryo. This technique has been used
only in mice (Meissner and Jaenisch 2006) and is highly
controversial for use in humans. Moreover, PSCs were
successfully generated from the late epiblast of post-im-
plementation embryos, called epiblast stem cells (EpiSCs),
with the same efficiency as blastocyst-mediated ICM
(Brambrink et al. 2006). However, there were some dif-
ferences in gene expression and epigenetic patterns
between EpiSCs and epiblast cells taken from naturally
fertilized embryos (Ding et al. 2009).
Another approach is cell fusion of adult human skin
cells with human ESCs in a milieu of some reprogramming
factors, as undertaken by Cowan et al. (2005). ‘‘Hybrid’’
cells resembled ESCs in terms of growth and division as
well as the expression of proteins typical for pluripotent
cells. One crucial obstacle is a problem for further clinical
use; the fused cells were tetraploids, with four copies of the
DNA in the nucleus. To date, the problem of extra DNA
removal has been unsolved. The method is now useful in
studying the course of reprogramming adult somatic cells.
The main advantage of SCNT over ESCs (embryo-
originated) is the presence of identical genes in the donor
and the pluripotent cells derived from its nucleus, which
lays a foundation for therapeutic cloning. The goal is based
on generating healthy tissues and organs to transplant them
into the patient/donor of the nucleus from his/her somatic
cells. This method may exclude the problem of immune
rejection and organ donation. Some experiments in a
mouse model supported the developmental potential of
ESCs generated by SCNT and their resemblance to ESCs
received from fertilized embryos in respect to DNA
microarray profiles, DNA methylated regions, gene-ex-
pression and transcriptional profiling, microRNA and
protein expression (Brambrink et al. 2006; Ding et al.
2009). Furthermore, compared to iPSCs, no effect of epi-
genetic memory of the donor cell type was reported in
SCNT-derived pluripotent cells, and fewer CpG sites in the
promoters retain methylation from parental cells (Ma et al.
2014). These cells may have therapeutic potential also in
tissue engineering, when they proliferate and differentiate
on scaffold bases. Tissue engineering trials were initialized
with myocardial tissue in a rat post-infarction model. The
method may also enable the treatment of atherosclerosis,
severe skin burns, diabetes mellitus and strokes. Moreover,
it was shown that SCNT-derived ESCs can help to correct
gene defects (Rideout et al. 2002) and complement neurons
in Parkinsonian mice (Tabar et al. 2008).
SCNT may also be useful to create a model for human
genetic diseases like Huntington’s disease by using the cell
lines for testing drugs and studying cell growth and
metabolism. However, the generation of human ESCs by
SCNT using aged nuclear donors is still problematic.
Nevertheless, introducing transgene encoding telomerase
activity could restore telomere length and improve cell
survival. Recently, Chung et al. (2014), using Tachibana’s
protocol (Tachibana et al. 2013), obtained SCNT-hESCs
taking the nuclei from dermal fibroblasts of 35- and
75-year-old males and demonstrated that the nuclear
reprogramming of human cells is possible despite age-as-
sociated changes. SCNT-derived cells can be used in
cancer diagnosis by checking carcinogenesis risk based on
genetic or epigenetic defects (Hochedlinger et al. 2004; Li
et al. 2003; Novak 2004). However, the epigenetic resetting
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connected with SCNT hinders proper disease representa-
tion (Jaenisch 2004).
Some issues remain unsolved. Cell availability limits
clinical application, and the cells are not fully immune
compatible (Mombaerts 2003). In addition, the donor egg
contains DNA located in the mitochondria, which excludes
complete DNA identity to the donor nucleus. And finally,
social resistance to human oocyte donation and a lack of
clear boundaries between therapeutic and reproductive
cloning are large issues.
Reprogramming Somatic Cells with Gene
Overexpression
The milestone in cell reprogramming was to generate
iPSCs without using embryos. Takahashi and Yamanaka
(2006) introduced 4 selected genes whose overexpression
was critical for pluripotency status (Oct4, Sox2, Klf4 and c-
Myc) to mouse embryonic fibroblasts (MEFs) and adult
tail-tip fibroblasts. The iPSCs from adult somatic cells were
similar to ESCs in terms of their morphology, proliferation,
pluripotent gene expression, epigenetic patterns, surface
antigens and telomerase activity.
These transcription factors change the epigenetic status
typical of differentiated cells by silencing retroviral trans-
genes; reactivating endogenous pluripotency genes; the
formation of bivalent chromatin domains in the promoters
of developmental genes; DNA hypo- and/or hyper-methy-
lation in imprinted gene loci; chromatin fibre
reorganization; and, possibly, reactivation of the inactive X
chromosome in female iPSCs (Li et al. 2014). OCT4 and
SOX2 are crucial to maintain pluripotency (Boyer et al.
2005; Loh et al. 2006), while KLF4 and c-MYC are proto-
oncogenic factors. In addition, c-MYC induces the global
acetylation of histone. High-density oligonucleotide arrays
conducted on human chromosomes 21 and 22 revealed as
many as 25,000 transcription factor binding site regions for
this ‘‘master regulator’’ (Cawley et al. 2004). Thus, c-MYC
largely promotes OCT4 and SOX2 binding to specific DNA
fragments (Fernandez et al. 2003). KLF4 is thought to be
involved in the inhibition of p53 protein, which downreg-
ulates NANOG expression during ESC differentiation
(Rowland et al. 2005). Further studies have shown that
NANOG is one of the most important pluripotency factors
and the gene set discovered by Takahashi and Yamanaka
(2006) may be even reduced to OCT4 overexpression with
extra molecule supplementation for successful
pluripotency.
Somatic cells can be reprogrammed (both X chromo-
somes are inactivated) and followed by injection in the
blastocyst they acquire the ability to differentiate into
various cell types and tissues that are derivatives of the
three embryonic germ layers. The second generation of
high quality iPSCs (Nanog-iPSCs) was selected by con-
struction of a Nanog-reporter under puromycin resistance
(Okita et al. 2007). This technique resulted in pluripotent
cells competent for germline transmission, successfully
generating live chimeric mice (Maherali et al. 2008;
Wernig et al. 2007).
Thus, a new perspective emerged in 2007 after the
successful generation of human PSCs from adult human
fibroblasts. The pluripotency status was assessed by
detection of the surface antigen: SSEA-3, SSEA-4, tumor
related antigens TRA-1-60, TRA-1-81 and expression of
NANOG. Other pluripotent properties included high
telomerase activity, high pluripotency potential towards the
cells originating from three embryonic layers and the
generation of teratomas in immunocompromised animals
(Takahashi et al. 2007). The technique has been considered
to be much easier than SCNT and circumvents ethical
controversies. Human iPSCs can be patient-specific, which
presents the possibility to screen new drugs in a close-
fitting toxicity model. Direct testing of the pluripotency of
iPSCs in humans is not possible because of the risk of
tumors, which is one of the reasons for the cell therapy
delay in clinical trials.
Although successes in embryonic stem cell isolation and
iPSC generation have been reported, differences between
iPSCs and hESCs still occur. In comparison to ESCs,
iPSCs exhibit lower developmental potential and differ-
entiation capacity, depending on various initial states of
pluripotency, different conditions of cell line maintenance,
epigenetic status originating from the tissue source (Kim
et al. 2010), and the distinct ability for the production of
intracellular growth factors. Hu et al. (2010) demonstrated
that iPSCs differentiate to human neurons with signifi-
cantly lower efficiency than ESCs, which may be the effect
of specific somatic cell genetic reprogramming. Another
study comparing ESCs and iPSCs with identical DNA
showed a distinct efficiency at incorporation into chimeric
mice and remarkably different gene activity on chromo-
some 12. Insufficient knowledge related to the molecular
basis of iPSC generation is one of the drawbacks of this
technique. One example is the immunogenic reaction
developed against some tissues derived from iPSCs,
stemming from unknown genetic and epigenetic defects
(Cao et al. 2014).
Chemically Induced PSCs
The latest development in the field of somatic cell repro-
gramming is a transgene-free approach. iPSCs may be
introduced to clinical trials after disposing exogenous
reprogramming factors. With time, studies of genetic
reprogramming allowed a gradual reduction in the number
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of pluripotency genes to be introduced to somatic cells.
The Oct4 transcription factor alone was sufficient when
adding the compound ‘‘VC6T’’ (valproic acid,
CHIR99021, 616452 and tranylcypromine) to generate
iPSCs in murine and human cells (Li et al. 2011; Zhu et al.
2010).
Hou et al. (2013) reported that after screening 10,000
small molecules, forskolin (cAMP agonist), 2-MeHT (2-
methyl-5-hydroxytryptamine) and D4476 (casein kinase
inhibitor) could also be a chemical substitute for Oct4. The
expression of Oct4 and Nanog was not observed. More-
over, their promoters were hypermethylated. For successful
reprogramming, the composition of additional molecules
was further required.
Optimization of the procedure with VC6T, DZNep (3-
Deazaneplanocin A), VC6TF (VC6T plus forskolin),
glycogen synthase kinase-3 and mitogen-activated protein
kinases was attempted. Cells termed chemically iPSCs
(CiPSCs), of ESC-like morphology with compatible gene
expression profile that differentiate into three germ layers,
were generated. The efficacy of this experimental process
was up to 0.2 % (comparable to reprogramming obtained
by classical transcription factors); that is, the generation of
1–25 CiPSC colonies from 50,000 plated MEFs. After
injection into the blastocyst, integration with the other
organs was detected, including the gonads, as well as
transmission to the following generation. Moreover, the
chimeric mice generated from these cells were completely
viable and healthy, evidence of a full reprogramming
process (Hou et al. 2013).
Further research established several essential com-
pounds for pluripotency induction: C (CHIR99021—a
glycogen synthase kinase 3 inhibitor), 6 (616452—TGF-b
inhibitor), F (forskolin) and Z (DZNep—a S-adenosyl
homocysteine hydrolase inhibitor; an epigenetic modula-
tor), and compound P (PD0325901), responsible for the
pluripotency circuit. In addition, optional ‘‘minimal
essential’’ booster compounds were identified: V (VPA), T
(Tranylcypromine, Pernate) and T (TTNPB—a synthetic
retinoic acid receptor ligand). CF6 molecules are thought
to induce an early phase of Sall4 and Sox2 overexpression,
DZNep, for the Oct4 gene by decreasing DNA methylation
at the late step of the chemical reprogramming stage.
Subsequently, these molecules activate genes associated
with pluripotency, for example the Nanog gene, and silence
Gata6 (Masuda et al. 2013). As a result, CiPSCs demon-
strate doubling time, alkaline phosphatase activity, DNA
methylation status and pluripotency markers with normal
karyotype and genetic integrity up to 13 passages, similar
to ESCs.
The CiPSC technique was successfully used in mouse
adult fibroblasts, mouse neonatal fibroblasts and adipose-
derived stem cells but not in human cells. However, the use
of this technique in humans seems to be only a matter of
time, although it probably will require some modifications.
Differences between Mice and Human
Pluripotency
Pluripotency can be considered in two states. Naı¨ve
pluripotent cells (mouse ESCs) were first obtained from
ICM cells derived from preimplantation mouse embryos
in vitro and were similar to ICM cells at embryonic day
4.5, capable of giving rise to chimeric animals with high
yield and insensitive to single cell dissociation. In female
mice, both X chromosomes were active (De Los Angeles
et al. 2012). The second (more rare) subpopulation is
known as primed PSCs, consisting of more developed cells.
This subpopulation originates from mouse EpiSCs biopsied
from early post-implantation embryos. In spite of creating
chimeras, in females only one chromosome X was active
and sensitivity to single cell dissociation occurred. Dif-
ferences were also noted in flatter colony morphology
(Huang et al. 2012). Human ESCs, although derived from
ICM, resembled mouse EpiSCs in terms of required growth
factors and X chromosome activity (De Los Angeles et al.
2012). Nevertheless, Gafni et al. (2013) managed to derive
human naı¨ve PSCs with similar features to mice counter-
parts. However, comparative computational analysis
revealed their similarity to the primed mice PSC state, in
respect to the cellular and differentiation-related response
(Ernst et al. 2015).
Research into the mechanisms regulating pluripotency
was conducted largely based on mouse iPSCs. Subse-
quently, some differences were found in pluripotent cells
originating from human and mice PSC lines (Schnerch
et al. 2010). Even before developing the protocol for
obtaining iPSCs across species, some disparities in estab-
lishing ESC lines were determined, including distinct
development, timing of isolation and global transcriptional
profile (Rao 2004; Sato et al. 2003). Morphologically,
human embryonic stem colonies do not override each other
and are flatter. As with iPSC culture, they require FGF-2
for self-renewal rather than leukemia inhibitory factor in
mice pluripotent cells (Amit et al. 2000; Matsuda et al.
1999). In turn, BMP, promoting self-renewal in mouse
ESCs, causes differentiation in human PSCs (Xu et al.
2005; Ying et al. 2003). Research suggests that the main
transcriptional network controlling pluripotency in mice
and humans is consistent. Detailed differences lie in dis-
tinct signals and external factors maintaining self-renewal
(Yu et al. 2007), as well as in their targets governing cell
fate; i.e., overexpression of the c-MYC factor resulting in
differentiation and apoptosis of human ESCs but not
murine ESCs (Cartwright et al. 2005).
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Some differences were also apparent during iPSC gen-
eration that can be explained by slower doubling time and
silencing kinetics of ectopically expressed genes in human
PSCs (Koch et al. 2006), which may have an impact on
lower production yield (Masaki et al. 2007). Although
Oct4, the master regulator of pluripotency, is essential for
reprogramming in mice and human PSCs, the effects of
gene knockout or increasing the level of Oct4 caused
spontaneous differentiation in a diverse manner for these
two species (Niwa et al. 2000; Rodriguez et al. 2007). The
functionality of Sox2 is much better known for mouse
iPSCs than for human pluripotent cells. In turn, the
induction of different differentiation pathways between
human and mice ESCs was shown in the case of Nanog
downregulation (Hyslop et al. 2005; Mitsui et al. 2003;
Zaehres et al. 2005). In comparison with human PSCs,
Kruppel-like factor (Klf) family members are upregulated
in mouse iPSCs, resulting in differences in self-renewal
regulation (Jiang et al. 2008). Additionally, the impact of
miRNAs on regulating pluripotency, including occupying
the promoters of Oct4, Sox2 and Nanog, is not without
significance. Interspecies distinctions in miRNA profiles
and their distribution in chromosomes may be reflected by
cell differentiation. The same applies to some genes that
may be not epigenetically conserved within particular
mammalian species (Ivanova et al. 2006). Also there are
some species-specific markers; e.g., SSEA-1 occurs in
mice but not in humans. All these differences suggest that
studies performed using mice cell lines cannot be directly
translated to the biology of human pluripotent cells. Thus,
the mechanism of differentiation and its regulatory path-
ways in human iPSCs must be more deeply understood for
wider applications of stem cell replacement therapy.
Finally, designing new functional assays for human iPSCs
could replace currently used animal-based models and
single cell assays.
Pluripotency Assessment
The key issue for conducting research on pure pluripotent
cell generation is assessing the quality of the method.
Investigating the scope of cell pluripotency is a funda-
mental stage prior to clinical applications (Table 1). A
normal phenotype initially allows for consideration of a
particular cell line to undergo the differentiation procedure
and later to be transplanted into the patient. One of the first
indicators is a high nuclear to cytoplasmic ratio. Moreover,
undifferentiated hESCs form compact multilayer colonies
with defined edges and high alkaline phosphatase activity
(Reubinoff et al. 2000). Cell immortality is connected to a
high level of telomerase activity (Thomson et al. 1998).
Pluripotency is also characterized by examining the level
of alkaline phosphatase. Finally, many specific epitopes
and nuclear transcription factors associated with pluripo-
tency can be recognized, proving its genetic function and
differentiation potential (Table 2).
The ability to form three embryonic germ layers can be
determined in vitro by culturing ESCs in suspension to
form embryoid bodies, cell aggregates which contain
derivatives of the mesoderm, endoderm and ectoderm
(Zeng et al. 2004). Analogous differentiation processes also
occur after PSCs implantation into a host animal, usually a
mouse. The standard pluripotency assay in vivo is based on
the generation of teratomas in SCID mice. The heteroge-
neous structures are basically encapsulated tumors made up
from cells at varying differentiation stages and of different
embryonic layer origin. Next, the teratomas are evaluated
for histopathology (Steiner et al. 2010). This method,
however, is subjected to poor reproducibility and a high
degree of variability.
Under more advanced verification, human ESCs are
subjected to direct differentiation into desired cellular lin-
eages. This homogenous population serves as an indicator
required for further cell transplantation consideration. It is
a proof of the pluripotency and differential flexibility of a
particular ESC line capable of forming different tissues.
Neural differentiation protocols are used to show ectoderm
direction (Nat et al. 2007), hepatocyte differentiation for
endoderm derivatives (Cai et al. 2007) and cartilage or
cardiac differentiation protocol for mesodermal fate
(Mummery et al. 2007; Qu et al. 2013).
A widely used easy and quick immunostaining method
for fixed pluripotent cells shows homogeneity in monolayer
culture. Nevertheless, it is a qualitative assay and it must be
used with a ‘‘negative control’’ to ensure background signal
suppression. Therefore, it must be carried out alongside
quantitative methods, as it is confirmed by images of
embryoid bodies disclosing pluripotency markers even
after a long period of partial cell differentiation (Bhat-
tacharya et al. 2005). Hence, quantitative reverse
transcription-polymerase chain reaction analysis, confirm-
ing stable and abundant levels of given marker expression,
is a necessary step. To evaluate the three main germline
lineages, markers must be appended with a view to the
neuro-ectoderm path being the main direction of hESCs
differentiation (Vallier et al. 2004). In turn, immunoblots
give semi-quantitative data related to protein markers.
Fluorescence-activated cell sorting (FACS) is a supple-
mentary test detecting different cellular populations within
hESC cultures (Silva and Smith 2008).
Researchers have also raised the relevance of the correct
karyotype. Prolonged ESCs culture causes copy number
variations and loss of heterozygosity resulting in altered
gene expression, precluding its clinical application (Narva
et al. 2010). Overall, human ESCs with normal karyotypes
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generate teratomas composed of only differentiated cells.
On the other hand, karyotypically irregular ESCs give rise
to teratocarcinomas containing undifferentiated cells,
which can indicate genetic abnormalities (Sidhu 2012).
This is the reason for the required karyotyping of
pluripotent cells designed for cellular therapies after each
10th passage in in vitro conditions. However, in iPSC
technology, some iPSC lines with normal karyotypes are
subjected to tumorigenic mutations acquired during or after
genetic reprogramming. For example, in a small area it
may come to multiplication of the BCL2L1 locus connected
with an anti-apoptotic factor (Amps et al. 2011). Thus, for
potential clinical use, they should be subjected to extensive
genetic screening. It is assumed that for PSC transplanta-
tion to the patient, genotyping with a genome-wide single
nucleotide polymorphism array including copy-number
variations and copy-number neutral loss-of-heterozygosity
regions will bring enough resolution to ensure proper
verification of genetic integrity, though it cannot replace
karyotyping, which additionally detects balanced translo-
cations and inversions.
In animal models, the pluripotency status is determined
by a blastocyst complementation assay. In this method,
cells are injected into the developing mouse blastocyst. In
the differentiating embryo, the formation of tissues origi-
nating from all three embryonic germ layers and chimeric
mice is expected (Hochedlinger and Jaenisch 2006). Tet-
raploid blastocyst complementation is a very valuable
pluripotency method to assess the degree of resemblance
between reprogrammed iPSCs and normal ESCs (Zhao
et al. 2010). As reported by Kang et al. (2009), using this
technique, iPS cell lines can generate full-term mice giving
the most stringent proof of full pluripotency. Tetraploid
embryos are generated by applying an electrical current
and fusing late two-cell-stage embryos to one-cell-stage
embryos collected from impregnated mice. iPSCs are
microinjected into the cavity of the tetraploid blastocyst
(4N) and transferred to pseudopregnant ICR strain (Insti-
tute of Cancer Research) mice. Viable animals form iPSC-
complemented ICR mice tetraploid embryos, demonstrat-
ing comparable iPSCs to ESCs potential. Given the ethical
limitations, the procedure is not used for human iPSCs.
Instead, many tests are conducted to compare iPSCs
with human ESCs; i.e., transcriptome, proteome, micro-
RNA content, epigenome and genome-wide CpG
methylation profiling cultured cells (Chin et al. 2009;
Guenther et al. 2010). In this regard, RNA arrays and mass
spectrometry are very powerful assays for detection
markers of pluripotency and differentiation. In addition,
comparative genomic hybridization arrays can be used to
determine genetic stability, while fluorescent in situ
hybridization can localize any possible aneuploidies (Ja-
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high-throughput DNA sequencing (ChIP-Seq) provides
essential information about chromatin organization and the
pattern of histone modifications near Oct-4 and Nanog
promoters and other critical genetic loci (Bibikova et al.
2008).
Techniques of PSC Derivation and Potential
Clinical Application
The greatest barrier for the medical use of embryonically
derived or autologous-induced PSCs is the safety of cell
transplantation. Another problem is the generation of a
sufficient quantity of purified and functionally active dif-
ferentiated cells. Moreover, there are conserved gene
expression networks which are common for tumorigenesis
and cells of pluripotent potential (Lee et al. 2013). In fact,
PSCs injected subcutaneously form teratoma-like tumors
and can extensively proliferate. This is a clear demon-
stration that PSC-derived differentiated cells must be very
pure before transplantation to the patient. In this respect,
ESCs can be considered as a better source than iPSCs with
transduced additional genes. However, prolonged in vitro
culture may lead to undesired changes at the gene or
chromosome level (previously described). Hence, many
researchers in the stem cell field are now engaged in
designing methods for purifying differentiated cells. For
this purpose, FACS and magnetic cell sorting are useful
tools, which can be further supported by applying cytotoxic
antibodies against pluripotency genes (Choo et al. 2008);
cell growth specific inhibitors, such as oleate synthesis
inhibitor (Ben-David et al. 2013); and inducible factors of
apoptosis with iCasp9 (Stasi et al. 2011) to remove all the
remaining pluripotent cells.
For ESC derivation, human zygote exploration is
impossible to avoid. However, immune rejection is a
problem due to the limited number of ESC lines. Matching
to highly polymorphic human leukocyte antigens (HLA) is
difficult in humans. Still, there are some advantages of
ESCs over iPSCs. They seem to have better genetic sta-
bility and are more carefully tested, which means that they
are safer for cellular therapies. Additionally, they have a
much higher ability for expansion and regenerative
potential than cord blood and mesenchymal stem cells.
Embryonic cells maintain their differentiation potential for
3–6 days after fertilization and can fulfil many goals of
regenerative medicine, such as replacing dead or damaged
cells/tissues or building human organs, in spite of their
allogenic origin.
Clinical-grade ESCs must comply with many require-
ments to minimize any possible risk for the recipient. They
must fulfil good manufacturing practice, preclude tumori-
genesis, and be successfully characterized with in vitro and
in vivo assays, including those of genetic stability. The first
clinical trials of differentiated oligodendrocytes in spinal
cord injury (Piltti et al. 2013) and retinal pigment epithe-
lium (RPE) transplanted to patients with Stargardt’s
macular dystrophy (Schwartz et al. 2015) reported no side
effects.
The primary expectations with respect to iPSCs are
related to immune rejection and ethical issues. However,
regardless of progress, there are still some hindrances to
clinical trials. The primary studies focused on developing
appropriate methods to generate sufficient quality iPSCs
with respect to the reprogramming factor, the vectors for
exogenous gene delivery and the sources of particular cell
types (Seki and Fukuda 2015).
The first principle of regenerative medicine is to avoid
the risk of tumor formation by reducing the pluripotential
gene set, particularly one containing protooncogenes. In
fact, it has been demonstrated that only Oct4 and Sox2 are
strictly required for pluripotency status, even when not
adding extra molecules. Research has concentrated on
omitting the c-Myc oncogene (Okita et al. 2008). Substi-
tutes of this gene have been found, including Tbx3 (Han
et al. 2010), Glis1 (Maekawa et al. 2011) and Zscan4 (Jiang
et al. 2013). Additionally, Montserrat et al. (2013) suc-
cessfully replaced Yamanaka factors with the cell lineage
specifiers OCT3/4 with GATA3, a mesodermal lineage
marker, and SOX2 with ectodermal marker ZNF521
(Montserrat et al. 2013).
The method of transgene delivery into somatic cells is
crucial for the clinical use of iPSCs (Table 3). At first, the
principal method of pluripotency induction was to use a
gene introduced by viral-origin vectors: retrovirals, such as
pMXs (Takahashi et al. 2007) or pMSCV (Hawley et al.
1994), and lentivirals (Table 4). These vectors ensured
high reprogramming efficiency (defined as the percentage
of GFP-positive iPSC colonies with appropriate morphol-
ogy, marked with a GFP-labelled transgene). Successful
reprogramming was effective in transgene silencing but a
certain risk was associated with the possibility of inser-
tional mutations to the genome because there is a chance
for such vectors to integrate randomly (to a genome),
potentially leading to the development of some disorders
bound to viral transgene reactivation. Moreover, pluripo-
tency genes, such as c-MYC and KLF4, classified as
protooncogenes, may induce tumor formation (Okita and
Yamanaka 2011) and so are not safe to use in cellular
therapy. Some approaches have delivered transcription
factors under a single promoter in a single virus, thus
reducing the chance of a transgene for mutational insertion
into the genome (Carey et al. 2009). In spite of genomic
integration, commonly used lentiviruses enabled even more
efficient transduction than retroviruses (Yu et al. 2007), but
were more resistant to silencing transgenes in the
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pluripotent state, which rules them out from clinical trials.
There is an oncogenic risk in differentiated cells, and
transgenes may interfere with functional genes. In turn, a
Cre-deletable lentivirus system was not fully effective
because LoxP sequence breaking genes remained in the
genome after cutting off the insert sequence.
The alternative option is the replacement of virus-origin
vectors with vectors that do not integrate into the genome,
like adenoviruses (Zhao et al. 2008) or the widely used
Sendai viruses with transient expression (Fusaki et al.
2009). Safer adenovirus vectors provide transient gene
expression without transferring residual transgenes (Harui
et al. 1999). Still, integration into the genome and low
efficiency are problematic. In turn, the Sendai virus
improves clinical potential by introducing negative-sense
single stranded RNA into the cytoplasm and not crossing
into the nucleus, precluding genomic insertion (Fusaki
et al. 2009). Expression of the transgene gradually silences,
with cell divisions preventing its reactivation. Any traces of
viral RNA can be removed through siRNA infection or a
higher temperature treatment (Ban et al. 2011; Nishimura
et al. 2011).
However, scientists hold their greatest hope for cellular
therapies in non-viral integration-free vectors by employ-
ing episomal plasmids (Okita et al. 2007); piggyback
transposons (Woltjen et al. 2009); the most effective EV
method (Yu et al. 2009a); human artificial chromosome
vectors (Hiratsuka et al. 2011) or minicircle DNAs
approved by the FDA (Jia et al. 2010); or proteins, RNAs
and small chemical molecules (Rajasingh 2012). Safety can
be achieved at the expense of decreased efficiency and
longer pluripotency activation; however, all these approa-
ches tend to apply to iPSCs for prospective clinical use.
Refined protocols with episomal vectors bearing com-
binations of OCT3/4, SOX2, KLF4, L-MYC, LIN28, and the
shRNA for the TP53 plasmid brought higher virus-free
pluripotency induction than previously (Okita et al. 2011,
2013). Another approach to eliminate residual transgenes is
the piggyBac transposon system based on piggyBac
transposase. Integration-free iPSCs were an advantage but
reprogramming efficiency needs to be improved (Woltjen
et al. 2009).
There are promising methods related to RNA-based
reprogramming. The method of direct delivery of syn-
thetically transcribed mRNAs in in vitro conditions
precluded endogenous antiviral cell defence and triggered
somatic cell reprogramming with higher efficiency com-
pared to retroviruses (Warren et al. 2010). Also, miRNAs
as pluripotency carriers are taken into account for potential
clinical use (Miyoshi et al. 2011). Specific mature miRNA
combinations through lentiviral transduction have the
capacity to reprogram somatic cells into iPSCs without
exogenous transcription factors. For example, the
expression of a miR302/367 cluster (comprised of 5 miR-
NAs) by miR367 activation initiates the process two-fold
more effectively than OCT4/SOX2/KLF4/MYC-derived
methods and precludes genes breaks or transgene reacti-
vation (Anokye-Danso et al. 2011). Simultaneously,
linkage with the HDAC-mediated pathway was deter-
mined, in which the miRNAs targets are Oct4 and Sox2
aimed to maintain cell homeostasis and pluripotency in
ESCs. The success of these experiments was confirmed by
the identification of pluripotency markers, teratoma for-
mation, chimeras and germline contribution. Additionally,
to bypass the innate immune response to viral molecules, a
synthetic RNA was successfully developed (Mandal and
Rossi 2013). Advances in this methodology may support
basic stem biology studies as well as high throughput of the
iPSC generation for clinical applications.
Similarly attractive for clinical use are cell-permeable
recombinant proteins (Kim et al. 2009), although very low
productivity (approximately 0.001 %) remains an obstacle
to wider implementation. Zhou et al. (2009), by fusing the
C-terminus of four proteins (gene products identified by
Yamanaka) with poly-arginine (11R), created recombinant
cells which were penetrated with reprogramming proteins.
Employing them, the protein-induced PSCs (piPSCs) were
generated from murine embryonic fibroblasts. Kim et al.
(2009) used the approach to generate stable iPSCs by
reprogramming human fibroblasts using OCT4, SOX2,
KLF4 and c-MYC proteins fused with cell-penetrating
peptides in HEK293 extracts with no further chemical
treatment. However, it must be emphasized that this is a
challenging method requiring a great deal of laboratory
experience and protein chemistry equipment, with a rather
low final yield. After comparing different types of iPSC
delivery in neuronal differentiation, piPSCs indicated
unlimited expansion without cellular senescence (Rhee
et al. 2011). However, some remaining undifferentiated
cells may induce tumors.
The most recent method with respect to the safety of
genetic reprogramming is the small-molecule methodology
introduced by Hou et al. (2013), who used seven small-
molecule compounds for iPSC generation (yet with low
efficiency at level of 0.2 %). This safe method constitutes a
promising potential tool for treating diseases and screening
systems due to compound permeability, convenient syn-
thesis, preservation, ready access, no immunogenic
response, easy handling and reasonable costs (Zhang et al.
2013). The small molecule function may be reversible and
was set up by optimizing its optimal concentration. On the
other hand, the method is time-consuming for routine use.
Reprogramming of mouse cell lasts approximately
40 days; in humans, it is estimated up to 60 days. Despite
the lack of mutagenesis, there is still a risk of genetic
instability. The epigenetic memory of CiPSCs was also not
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analysed. Its disadvantage precludes rapid clinical use
because of the low efficiency conversion of somatic cells to
iPSCs (range 0.1–1 %). To date, successful reprogramming
was achieved in mice (Hou et al. 2013). In humans, suc-
cessful reprogramming without transcription factors was
conducted only with cell extracts and/or proteins (Kim
et al. 2009; Zheng et al. 2012), but possible clinical
advantages may push the technology of human small
molecule-derived iPSCs in a relatively short time.
Advances in this direction have the potential to provide an
unlimited cell supply to regenerative medicine of the
desired cell types. It is assumed that potential application
will be possible if CiPSCs are generated from patient-
specific cells and/or human somatic cells possessing vari-
ous HLA types at efficiencies exceeding 0.1 % (Higuchi
et al. 2014).
To date, a variety of somatic cell types have been
selected for successful reprogramming procedures for
iPSCs with subsequent differentiation to a broad range of
different cells, including germ cells with functional abili-
ties (Aasen and Izpisu´a Belmonte 2010; Haase et al. 2009).
Skin fibroblasts are the ‘‘gold standard’’ for the technique
of genetic reprogramming and any other approaches should
be referred to it (Table 5). These cells, as well as ker-
atinocytes, are convenient for non-invasive sampling,
which is desired in cellular therapies (Aasen and Izpisu´a
Belmonte 2010). In this regard, dental pulp stem cells,
mesenchymal stromal cells, oral gingival and mucosal
fibroblasts, and peripheral blood cells are also advanta-
geous (Egusa et al. 2010; Miyoshi et al. 2010; Oda et al.
2010; Tamaoki et al. 2010). Nonetheless, epithelial cells
are supposed to be more susceptible to reprogramming,
possibly because of a lack of the mesenchymal-to-epithe-
lial transition. In addition, iPSCs can be derived not only
from normal cell types but also from primary cancer and
malignant cells. The significant progress made in this field
in recent years provides a perspective for a patient-tailored
cellular therapy source and a drug testing target without
using human embryos and with a limited chance for
immune rejection. In addition, the iPSC technique does not
require costly and complex equipment and is quite simple
to perform.
Undoubtedly, one of the troublesome obstacles to
implement the iPSC technology in clinical applications,
such as personalized cell therapy, is line-to-line iPSC
variability resulting in different differentiation fates,
tumorigenesis, and the risk of global gene expression
depending on particular culture conditions (Newman and
Cooper 2010). Also, donor cell types may epigenetically
influence the differentiation tendency (Bar-Nur et al.
2011). Moreover, many protocols of iPSC generation have
been successful in mice but yield different effects in
humans. Thus, some differences between iPSC lines still
require documentation of the genetic and epigenetic pro-
files for appropriate iPSC classification and defining their
self-renewal ability, differentiation potential and safety
(concerning possible dedifferentiation rate). For instance,
some iPSC clones differentiating into a neural lineage were
prone to form tumors after transplantation to mouse brains.
Gene expression and DNA methylation analysis of undif-
ferentiated cells revealed the activation of genes with long
terminal repeats of specific HHLA1 (human endogenous
retrovirus-H LTR-associating 1) sequences (Koyanagi-Aoi
et al. 2013). Similarly, an undifferentiated iPSC fraction
was identified by Yamashita et al. (2013). During in vitro
cartilage tissue engineering, some portion of the iPSCs was
left in a pro-oncogenic state and a glandular epithelial
tumor formed in mice, in spite of normal morphology,
plating efficiency, teratoma forming ability and normal
karyotype in in vitro culture. Thus, finding universal safety
indicators is a challenge for regenerative medicine utilizing
iPSCs in patients.
The answer to these obstacles could be novel strategies
of iPSC protocol modifications focusing on the imple-
mentation of personalized cellular replacement therapy
and/or other biomedical applications, such as disease
modelling and pharmaceutical studies. For instance, hepa-
tocytes are considered to be challenging targets for
regenerative medicine. This year in the field of hepatology,
human self-renewing hepatic lineage-oriented stem cells
were generated, which proved the significance of opti-
mizing culture conditions. Modifications significantly
determined cellular commitment in vitro. These specific
iPSCs autonomously and preferentially differentiate into
hepatic-like cells without extra growth factors, chemical
compounds and gene transfer (Ishikawa et al. 2015). Cur-
rently, research is being conducted in other directions.
Recently, human fibroblasts were directly reprogrammed
by lentiviral transduction of three selected factors. This
technique generated stable lines of human induced hepa-
tocytes that possessed the ability to restore liver function in
a mouse model (Huang et al. 2014). Ectopic overexpres-
sion of hepatic determination factors along with maturation
factors resulted in cells with metabolic activities, hepato-
toxin sensitivity and expression profile comparable with
primary human hepatocytes (Du et al. 2014). Apart from
direct cell lineage conversion successfully changing the
fate of somatic cells, another promising approach is
establishing homogenous populations of progenitor cells
from ESCs or iPSCs. In this way, Cheng et al. (2012)
produced non-tumorigenic continuously replicating endo-
dermal progenitor lines with numerous lineage derivatives
such as hepatocytes and pancreatic b-cells. They might be
a powerful source of undifferentiated tissues, and a more
efficient and safer starting point for transplantation thera-
pies. In turn, disappointing results of iPS-derived
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hepatocytes in terms of human serum albumin production,
repopulation of cells in the liver and therapeutic safety
prompted some researchers to develop shortcut repro-
gramming of human fibroblasts omitting the pluripotent
intermediate stage (Zhu et al. 2014). Following the pro-
cedure, hepatocytes originated from endodermal progenitor
cells proliferated extensively in vivo and revealed adult
human primary hepatocyte functions.
Concluding Remarks
PSCs are a huge hope in regenerative medicine in terms of
cellular therapy for the treatment of a variety of the diseases
of civilization. After cloning Dolly the sheep from a mature
somatic cell in 1997, the next breakthrough was the isolation
of human ESCs from early embryos and their in vitro culture
in a Petri dish. Another milestone in this field was the
development of an induced PSC procedure without the
necessity of embryos, with the emergence of tremendous
potential for the exploitation of autologous stem cells.
Recently, the FDA approved the first clinical trials using
PSCs in curing macular degeneration (Schwartz et al. 2012)
and spinal cord injury (Chapman and Scala 2012). In Japan,
the first case of iPSC technology application in the clinic was
reported in 2014. In this trial, a RPE cell sheet generated
from iPSCs was engrafted to a patient suffering from
exudative age-relative macular degeneration (Takahashi
2014). There are still some unsolved aspects for the imple-
mentation of the cell therapy. The broad application of PSCs
with targeted differentiation can be a powerful tool for
studying early embryonic developmental pathways, the
etiology of disorders and drug toxicology testing (Rol-
letschek et al. 2004). Progress in techniques of stem cell (and
their descendants) isolation, maintenance and differentia-
tion is a real chance to meet the high expectations of
regenerative medicine.
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